How do I buy Opus Genetics, Inc. Common Stock (IRD) stock?

Buying Opus Genetics, Inc. Common Stock (IRD) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "IRD", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy IRD by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for IRD on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Opus Genetics, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Opus Genetics, Inc. Common Stock (IRD) pay dividends?

At the moment, Opus Genetics, Inc. Common Stock (IRD) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track IRD's performance via the price chart in the Gotrade app.

Is buying IRD on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy IRD?

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too. The market is closed on US public holidays. The Gotrade app shows whether the market is open.

How do I tell if IRD is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Opus Genetics, Inc. Common Stock (IRD) Stock Price: Nov 11 Close $4.31

Latest news

MarketBeat

Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval

PositiveIRDOctober 25, 2026

MarketBeatPositive

Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval

IRD

Stocktwits

Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment

IRDOctober 16, 2026

Stocktwits

Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment

IRD

Stocktwits

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

IRDOctober 12, 2026

Stocktwits

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

IRD

Stocktwits

IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial

IRDSeptember 9, 2026

Stocktwits

IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial

IRD

Zacks Investment Research

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

IRDAugust 6, 2026

Zacks Investment Research

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

IRD

MarketBeat

Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst

IRDMay 26, 2026

MarketBeat

Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst

IRD

Zacks Investment Research

News tone: automated (AI) classification of the article's content, not a price prediction.

About Opus Genetics, Inc. Common Stock

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

SectorHealthcare

IndustryBiotechnology

Employees27

CEODr. George Magrath M.B.A., M.D., M.S.

IPO DateMay 23, 2005

HeadquartersDurham, NC

Key Executives

Name	Title	Year Born
Dr. George Magrath M.B.A., M.D., M.S.	CEO & Director	1985
Mr. Joseph K. Schachle MBA	Chief Operating Officer	1965
Dr. Benjamin R. Yerxa Ph.D.	President & Director	1966
Dr. Ashwath Jayagopal M.B.A., Ph.D.	Chief Scientific & Development Officer	1983
Mr. Chris Ernst	Chief Technology Officer	—
Ms. Jenny Kobin	Investor Relations Officer	—
Mr. Bernhard Hoffmann M.B.A.	Senior Vice President of Corporate Development & Secretary	1956
Ms. Amy Zaremba Rabourn C.P.A., MAcc	Head of Financial Quality Assurance	1981
Ms. Bindu Manne	Head of Market Development & Commercialization	—
Ms. Sally Tucker Ph.D.	Chief Medical Officer & Senior Vice President of Clinical Development	—

Fundamentals

Valuation

Price-to-sales ratio22.82

Price-to-book value-27.10

Profitability

Return on Equity1148.00%

Return on Assets-175.00%

Return on Sales-1090.00%

Gross margin (latest quarter)100.00%

EBITDA$-107.36M

Trading

Average volume1,327,023

Source: third-party data provider, as of November 13, 2026

Technical indicators

RSI 14: 55.53
MACD 12/26/9: -0.03
EMA 9 of MACD: -0.13
MACD histogram: 0.10
SMA 50: $4.51; Price below SMA 50
EMA 50: $4.19; Price above EMA 50
SMA 200: $4.25; Price above SMA 200
EMA 200: $3.96; Price above EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst views

6 analyst ratings

Third-party analyst opinion, not a recommendation from Gotrade.

Analyst consensus:Buy

100% Buy

0% Hold

0% Sell

Analyst price target

Low: $11.00
Average: $13.83
High: $17.00

HC Wainwright & Co.

Matthew Caufield

Buy

Target price

$14.00

Wedbush

Yun Zhong

Buy

Target price

$13.00

RBC Capital

Lisa Walter

Buy

Target price

$11.00

BTIG

Thomas Shrader

Buy

Target price

$12.00

Chardan Capital

Andreas Argyrides

Buy

Target price

$16.00

Citizens

Jonathan Wolleben

Buy

Target price

$17.00

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2026	-7.6	+79.3	+5.1	+9.0	-15.2	-0.2	-11.2	-0.5	+26.4	-18.6	+16.5

Compare stocks

IRD

Buy IRD

Market cap

$416.58M

-

Price / Earnings ratio

-3.30

-

Price / Sales ratio

22.82

-

Dividend yield

0.00%

-

Average volume

1,327,023

-

Earnings per share

$-1.29

-

Opus Genetics, Inc. Common Stock (IRD) Stock

Key stats

Compare with IRD

Recent news

Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval

Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval

Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment

Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial

IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval

Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval

Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment

Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial

IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst

Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates

Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates

Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates

About Opus Genetics, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade